This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Comparison of Buprenorphine and Methadone - 3

This study has been completed.
Sponsor:
Collaborator:
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000334
First received: September 20, 1999
Last updated: January 30, 2017
Last verified: December 2002
  Purpose
The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.

Condition Intervention Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacological Comparison of Buprenorphine and Methadone

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Withdrawal severity
  • Opiate agonist symptoms

Estimated Enrollment: 0
Actual Study Start Date: December 1, 2002
Study Completion Date: January 15, 2005
Primary Completion Date: November 1, 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   23 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000334

Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington D.C. Veterans Affairs Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00000334     History of Changes
Other Study ID Numbers: NIDA-3-0009-3
Y01-3-0009-3
Study First Received: September 20, 1999
Last Updated: January 30, 2017

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Methadone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Antitussive Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on July 26, 2017